Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Inflamm Res. 2014 May 30;63(9):703–710. doi: 10.1007/s00011-014-0743-3

Figure 1. Biglycan up-regulates ICAM-1 expression and MCP-1 release in human AVICs.

Figure 1

Human AVICs from normal valves were treated with biglycan (BGN; 0.05, 0.10 and 0.20 μg/mL) for 48 h. A. Representative immunoblots of four separate experiments and densitometric data show dose-dependent induction of ICAM-1 by biglycan. B. Biglycan promoted the release of MCP-1, but had no effect on IL-6 release. Values are means ± SE. n = 4; *P<0.05 vs. untreated control.